GrippePaysBasV1, Main, Exploration, bibRecord, 000149

Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.

Identifieur interne : 000149 ( Main/Exploration ); précédent : 000148; suivant : 000150

Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.

Auteurs : Giedre Gefenaite [Pays-Bas] ; Margot Tacken ; Jens Bos ; Irina Stirbu-Wagner ; Joke C. Korevaar ; Ronald P. Stolk ; Bert Wolters ; Marc Bijl ; Maarten J. Postma ; Jan Wilschut ; Kristin L. Nichol ; Eelko Hak

Source :

PloS one [ 1932-6203 ] ; 2013.

RBID : pubmed:23840413

Descripteurs français

KwdFr :
- Adjuvants immunologiques (administration et posologie), Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Femelle (MeSH), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Grippe humaine (virologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Pays-Bas (MeSH), Polysorbates (administration et posologie), Sous-type H1N1 du virus de la grippe A (immunologie), Squalène (administration et posologie), Vaccination (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Études cas-témoins (MeSH), Études rétrospectives (MeSH).
MESH :
- administration et posologie : Adjuvants immunologiques, Polysorbates, Squalène, Vaccins antigrippaux.
- immunologie : Grippe humaine, Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- virologie : Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Mâle, Pays-Bas, Vaccination, Études cas-témoins, Études rétrospectives.
Wicri :
- geographic : Pays-Bas.

English descriptors

KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adolescent (MeSH), Adult (MeSH), Case-Control Studies (MeSH), Female (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Male (MeSH), Middle Aged (MeSH), Netherlands (MeSH), Polysorbates (administration & dosage), Retrospective Studies (MeSH), Squalene (administration & dosage), Vaccination (MeSH), Young Adult (MeSH).
MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Influenza Vaccines, Polysorbates, Squalene.
- geographic : Netherlands.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Case-Control Studies, Female, Humans, Male, Middle Aged, Retrospective Studies, Vaccination, Young Adult.

Abstract

INTRODUCTION

Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.

METHODS

VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.

RESULTS

Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.

CONCLUSIONS

Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.

DOI: 10.1371/journal.pone.0066125
PubMed: 23840413
PubMed Central: PMC3688717

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000138
to stream Main, to step Curation: 000138

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.</title>
<author><name sortKey="Gefenaite, Giedre" sort="Gefenaite, Giedre" uniqKey="Gefenaite G" first="Giedre" last="Gefenaite">Giedre Gefenaite</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands. g.gefenaite@umcg.nl</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
<orgName type="university">Université de Groningue</orgName>
</affiliation>
</author>
<author><name sortKey="Tacken, Margot" sort="Tacken, Margot" uniqKey="Tacken M" first="Margot" last="Tacken">Margot Tacken</name>
</author>
<author><name sortKey="Bos, Jens" sort="Bos, Jens" uniqKey="Bos J" first="Jens" last="Bos">Jens Bos</name>
</author>
<author><name sortKey="Stirbu Wagner, Irina" sort="Stirbu Wagner, Irina" uniqKey="Stirbu Wagner I" first="Irina" last="Stirbu-Wagner">Irina Stirbu-Wagner</name>
</author>
<author><name sortKey="Korevaar, Joke C" sort="Korevaar, Joke C" uniqKey="Korevaar J" first="Joke C" last="Korevaar">Joke C. Korevaar</name>
</author>
<author><name sortKey="Stolk, Ronald P" sort="Stolk, Ronald P" uniqKey="Stolk R" first="Ronald P" last="Stolk">Ronald P. Stolk</name>
</author>
<author><name sortKey="Wolters, Bert" sort="Wolters, Bert" uniqKey="Wolters B" first="Bert" last="Wolters">Bert Wolters</name>
</author>
<author><name sortKey="Bijl, Marc" sort="Bijl, Marc" uniqKey="Bijl M" first="Marc" last="Bijl">Marc Bijl</name>
</author>
<author><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J" last="Postma">Maarten J. Postma</name>
</author>
<author><name sortKey="Wilschut, Jan" sort="Wilschut, Jan" uniqKey="Wilschut J" first="Jan" last="Wilschut">Jan Wilschut</name>
</author>
<author><name sortKey="Nichol, Kristin L" sort="Nichol, Kristin L" uniqKey="Nichol K" first="Kristin L" last="Nichol">Kristin L. Nichol</name>
</author>
<author><name sortKey="Hak, Eelko" sort="Hak, Eelko" uniqKey="Hak E" first="Eelko" last="Hak">Eelko Hak</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23840413</idno>
<idno type="pmid">23840413</idno>
<idno type="doi">10.1371/journal.pone.0066125</idno>
<idno type="pmc">PMC3688717</idno>
<idno type="wicri:Area/Main/Corpus">000138</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000138</idno>
<idno type="wicri:Area/Main/Curation">000138</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000138</idno>
<idno type="wicri:Area/Main/Exploration">000138</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.</title>
<author><name sortKey="Gefenaite, Giedre" sort="Gefenaite, Giedre" uniqKey="Gefenaite G" first="Giedre" last="Gefenaite">Giedre Gefenaite</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands. g.gefenaite@umcg.nl</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
<orgName type="university">Université de Groningue</orgName>
</affiliation>
</author>
<author><name sortKey="Tacken, Margot" sort="Tacken, Margot" uniqKey="Tacken M" first="Margot" last="Tacken">Margot Tacken</name>
</author>
<author><name sortKey="Bos, Jens" sort="Bos, Jens" uniqKey="Bos J" first="Jens" last="Bos">Jens Bos</name>
</author>
<author><name sortKey="Stirbu Wagner, Irina" sort="Stirbu Wagner, Irina" uniqKey="Stirbu Wagner I" first="Irina" last="Stirbu-Wagner">Irina Stirbu-Wagner</name>
</author>
<author><name sortKey="Korevaar, Joke C" sort="Korevaar, Joke C" uniqKey="Korevaar J" first="Joke C" last="Korevaar">Joke C. Korevaar</name>
</author>
<author><name sortKey="Stolk, Ronald P" sort="Stolk, Ronald P" uniqKey="Stolk R" first="Ronald P" last="Stolk">Ronald P. Stolk</name>
</author>
<author><name sortKey="Wolters, Bert" sort="Wolters, Bert" uniqKey="Wolters B" first="Bert" last="Wolters">Bert Wolters</name>
</author>
<author><name sortKey="Bijl, Marc" sort="Bijl, Marc" uniqKey="Bijl M" first="Marc" last="Bijl">Marc Bijl</name>
</author>
<author><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J" last="Postma">Maarten J. Postma</name>
</author>
<author><name sortKey="Wilschut, Jan" sort="Wilschut, Jan" uniqKey="Wilschut J" first="Jan" last="Wilschut">Jan Wilschut</name>
</author>
<author><name sortKey="Nichol, Kristin L" sort="Nichol, Kristin L" uniqKey="Nichol K" first="Kristin L" last="Nichol">Kristin L. Nichol</name>
</author>
<author><name sortKey="Hak, Eelko" sort="Hak, Eelko" uniqKey="Hak E" first="Eelko" last="Hak">Eelko Hak</name>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Case-Control Studies (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Netherlands (MeSH)</term>
<term>Polysorbates (administration & dosage)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Squalene (administration & dosage)</term>
<term>Vaccination (MeSH)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term>
<term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Grippe humaine (immunologie)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Grippe humaine (virologie)</term>
<term>Humains (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Pays-Bas (MeSH)</term>
<term>Polysorbates (administration et posologie)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Squalène (administration et posologie)</term>
<term>Vaccination (MeSH)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Études cas-témoins (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Influenza Vaccines</term>
<term>Polysorbates</term>
<term>Squalene</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Netherlands</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Polysorbates</term>
<term>Squalène</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza Vaccines</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Case-Control Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Retrospective Studies</term>
<term>Vaccination</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Pays-Bas</term>
<term>Vaccination</term>
<term>Études cas-témoins</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Pays-Bas</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b>
</p>
<p>Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23840413</PMID>
<DateCompleted><Year>2014</Year>
<Month>02</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>8</Volume>
<Issue>6</Issue>
<PubDate><Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.</ArticleTitle>
<Pagination><MedlinePgn>e66125</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0066125</ELocationID>
<Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gefenaite</LastName>
<ForeName>Giedre</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands. g.gefenaite@umcg.nl</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tacken</LastName>
<ForeName>Margot</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bos</LastName>
<ForeName>Jens</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Stirbu-Wagner</LastName>
<ForeName>Irina</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Korevaar</LastName>
<ForeName>Joke C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Stolk</LastName>
<ForeName>Ronald P</ForeName>
<Initials>RP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wolters</LastName>
<ForeName>Bert</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bijl</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Postma</LastName>
<ForeName>Maarten J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wilschut</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nichol</LastName>
<ForeName>Kristin L</ForeName>
<Initials>KL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hak</LastName>
<ForeName>Eelko</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>06</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C089950">MF59 oil emulsion</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7QWM220FJH</RegistryNumber>
<NameOfSubstance UI="D013185">Squalene</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>02</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>05</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>7</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>7</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>2</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23840413</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0066125</ArticleId>
<ArticleId IdType="pii">PONE-D-13-08339</ArticleId>
<ArticleId IdType="pmc">PMC3688717</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Int J Biomed Comput. 1996 Jul;42(1-2):35-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8880267</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2012 Jun;54(2):135-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22398034</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Fam Pract. 2008 Aug;25(4):312-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18562335</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 May 22;58(19):521-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19478718</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2009 Jul;34(1):56-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19213779</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2009 Aug 20;460(7258):1021-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19672242</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1945-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19745214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Aug 31;28(38):6203-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20650340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2011 Jan 1;203(1):32-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21148494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2010 Dec 16;363(25):2416-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21158658</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2011 Jan;8(1):e1000388</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21379316</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2011 May;52(10):1203-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21507917</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2011;16(15). pii: 19843</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21507318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ageing Res Rev. 2011 Jul;10(3):379-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21055484</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Aug 11;29(35):5919-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21723358</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2011 Aug;18(8):1358-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21715575</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2011;11:196</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21767348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(8):e23085</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21857999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Jul 13;30(33):5030-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22472791</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Jan 30;31(6):900-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23246546</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Intern Med. 2012 Mar 26;172(6):484-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22371873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):661-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18327857</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Pays-Bas</li>
</country>
<region><li>Groningue (province)</li>
</region>
<settlement><li>Groningue</li>
</settlement>
<orgName><li>Université de Groningue</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Bijl, Marc" sort="Bijl, Marc" uniqKey="Bijl M" first="Marc" last="Bijl">Marc Bijl</name>
<name sortKey="Bos, Jens" sort="Bos, Jens" uniqKey="Bos J" first="Jens" last="Bos">Jens Bos</name>
<name sortKey="Hak, Eelko" sort="Hak, Eelko" uniqKey="Hak E" first="Eelko" last="Hak">Eelko Hak</name>
<name sortKey="Korevaar, Joke C" sort="Korevaar, Joke C" uniqKey="Korevaar J" first="Joke C" last="Korevaar">Joke C. Korevaar</name>
<name sortKey="Nichol, Kristin L" sort="Nichol, Kristin L" uniqKey="Nichol K" first="Kristin L" last="Nichol">Kristin L. Nichol</name>
<name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J" last="Postma">Maarten J. Postma</name>
<name sortKey="Stirbu Wagner, Irina" sort="Stirbu Wagner, Irina" uniqKey="Stirbu Wagner I" first="Irina" last="Stirbu-Wagner">Irina Stirbu-Wagner</name>
<name sortKey="Stolk, Ronald P" sort="Stolk, Ronald P" uniqKey="Stolk R" first="Ronald P" last="Stolk">Ronald P. Stolk</name>
<name sortKey="Tacken, Margot" sort="Tacken, Margot" uniqKey="Tacken M" first="Margot" last="Tacken">Margot Tacken</name>
<name sortKey="Wilschut, Jan" sort="Wilschut, Jan" uniqKey="Wilschut J" first="Jan" last="Wilschut">Jan Wilschut</name>
<name sortKey="Wolters, Bert" sort="Wolters, Bert" uniqKey="Wolters B" first="Bert" last="Wolters">Bert Wolters</name>
</noCountry>
<country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Gefenaite, Giedre" sort="Gefenaite, Giedre" uniqKey="Gefenaite G" first="Giedre" last="Gefenaite">Giedre Gefenaite</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippePaysBasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000149 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000149 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippePaysBasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23840413
   |texte=   Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23840413" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippePaysBasV1

This area was generated with Dilib version V0.6.35.
Data generation: Mon Aug 10 10:18:30 2020. Site generation: Sat Mar 27 13:53:34 2021

	Serveur d'exploration sur la grippe aux Pays-Bas
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe aux Pays-Bas

Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.

Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki